Potential Cystic Fibrosis Therapy Gets FDA Fast Track Approval, Clinical Tests to Follow
Proteostasis Therapeutics, Inc., announced that it recently received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for PTI-428, an investigational oral treatment for cystic fibrosis (CF). CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, resulting in a disruption of ion…